Lung cancer remains the leading cause of cancer deaths in the United States. In the past
decade, significant advances have been made in the science of non–small cell lung cancer …

Smoking cessation has reduced the incidence of lung cancer. The authors of this review
discuss recent progress in diagnostic and treatment approaches, including molecular …

Summary Lung cancer in East Asia is characterized by a high percentage of never-smokers,
early onset and predominant EGFR mutations. To illuminate the molecular phenotype of this …

Introduction KRAS mutations have been recognized as undruggable for many years.
Recently, novel KRAS G12C inhibitors, such as sotorasib and adagrasib, are being …

Lung neoplasms are the leading cause of death by cancer worldwide. Non-small cell lung
cancer (NSCLC) constitutes more than 80% of all lung malignancies and the majority of …

Targeted therapies are substantially changing the management of lung cancers. These
treatments include drugs that target driver mutations, those that target presumed important …

In recent years, there has been a major paradigm shift in the management of non-small cell
lung cancer (NSCLC). NSCLC should now be further sub-classified by histology and driver …

The epidermal growth factor receptor (EGFR) is a cell-surface receptor belonging to ErbB
family of tyrosine kinase and it plays a vital role in the regulation of cell proliferation, survival …

Activation of the EGFR, KRAS, and ALK oncogenes defines 3 different pathways of
molecular pathogenesis in lung adenocarcinoma. However, many tumors lack activation of …

Elucidating the spectrum of epithelial-mesenchymal transition (EMT) and mesenchymal-
epithelial transition (MET) states in clinical samples promises insights on cancer progression …